AOP Health Presents New Findings Regarding Consistent Hematologic Response of Patients With polycythaemia vera

AOP Health announced new results on ropeginterferon alfa-2b (BESREMi®) from its clinical study CONTINUATION-PV in patients with polycythaemia vera (PV), a rare blood cancer. Professor Heinz Gisslinger

Related Keywords

Austria ,Vienna ,Wien ,Kurt Krejcy ,Lylia Sivcheva ,Halyna Pylypenko ,Petr Dulicek ,Pencho Georgiev ,Vera Yablokova ,Dorota Krochmalczyk ,Robert Kralovics ,Jean Jacques Kiladjian ,Arpad Illes ,Miklos Egyed ,Christoph Klade ,Hansc Hasselbalch ,Polycythaemia Vera ,Heinz Gisslinger ,European Haematology Association ,European Hematology Association ,Aop Health ,Study Group ,Pharmaceuticals Gmb ,University Of Vienna ,Health Group ,Medical University ,Liana Gercheva Kyuchukova ,Victoria Empson ,Annual Meeting June ,Pharmaceuticals Gmbh ,Middle East ,Gefallene Big Techs ,Health ,Presents ,Findings ,Egarding ,Consistent ,Aematologic ,Response ,Patients ,Ith ,Olycythaemia ,Vera ,